These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 12949548)

  • 1. The closure of Sugen.
    Levitzki A
    Nat Biotechnol; 2003 Sep; 21(9):969. PubMed ID: 12949548
    [No Abstract]   [Full Text] [Related]  

  • 2. Sugen falls as casualty of Pfizer-Pharmacia merger.
    Garber K
    Nat Biotechnol; 2003 Jul; 21(7):722-3. PubMed ID: 12833079
    [No Abstract]   [Full Text] [Related]  

  • 3. Roche and Igen in shotgun wedding.
    Bouchie A
    Nat Biotechnol; 2003 Sep; 21(9):958. PubMed ID: 12949542
    [No Abstract]   [Full Text] [Related]  

  • 4. Does biotech M&A benefit investors?
    Jacobs T
    Nat Biotechnol; 2004 Sep; 22(9):1085. PubMed ID: 15340472
    [No Abstract]   [Full Text] [Related]  

  • 5. UK biotech sector loses flagship PowderJect to Chiron.
    Mitchell P
    Nat Biotechnol; 2003 Jul; 21(7):717. PubMed ID: 12833073
    [No Abstract]   [Full Text] [Related]  

  • 6. Antiinfective biotechs face partnering gap.
    Sheridan C
    Nat Biotechnol; 2005 Feb; 23(2):155-6. PubMed ID: 15696131
    [No Abstract]   [Full Text] [Related]  

  • 7. Is Elan a turnaround?
    Jacobs T
    Nat Biotechnol; 2003 Sep; 21(9):985. PubMed ID: 12949557
    [No Abstract]   [Full Text] [Related]  

  • 8. Earlier stage biotechs attract partners.
    Ratner M
    Nat Biotechnol; 2005 May; 23(5):509. PubMed ID: 15877052
    [No Abstract]   [Full Text] [Related]  

  • 9. Biotechnology partnerships--medicine for an ailing industry?
    DeLamarter J
    Nat Biotechnol; 2003 Aug; 21(8):847-8. PubMed ID: 12894192
    [No Abstract]   [Full Text] [Related]  

  • 10. Changing partners.
    Nat Biotechnol; 2002 Sep; 20(9):855. PubMed ID: 12205487
    [No Abstract]   [Full Text] [Related]  

  • 11. GlaxoSmithKline, Pfizer to merge HIV drug units in new company.
    AIDS Read; 2009; 19(6):206. PubMed ID: 19642236
    [No Abstract]   [Full Text] [Related]  

  • 12. Amgen's Japan deal.
    Ratner M
    Nat Biotechnol; 2008 Apr; 26(4):366. PubMed ID: 18392006
    [No Abstract]   [Full Text] [Related]  

  • 13. Hyseq-Variagenics merger signals end of the line.
    Hodgson J
    Nat Biotechnol; 2003 Jan; 21(1):5. PubMed ID: 12511895
    [No Abstract]   [Full Text] [Related]  

  • 14. Genentech makes its first-ever acquisition.
    Hollmer M
    Nat Biotechnol; 2007 Jan; 25(1):4-5. PubMed ID: 17211375
    [No Abstract]   [Full Text] [Related]  

  • 15. A reprise for collaborative financing in biotech.
    Ransom J
    Nat Biotechnol; 2006 Aug; 24(8):873-4. PubMed ID: 16900110
    [No Abstract]   [Full Text] [Related]  

  • 16. The term sheet tango.
    Willey T; Parsigian D
    Nat Biotechnol; 2003 Jul; 21 Suppl():BE29-30. PubMed ID: 12874974
    [No Abstract]   [Full Text] [Related]  

  • 17. Evolving symbiosis--venture capital and biotechnology.
    Bradford TC
    Nat Biotechnol; 2003 Sep; 21(9):983-4. PubMed ID: 12949556
    [No Abstract]   [Full Text] [Related]  

  • 18. Genomics companies shop around for chemical expertise.
    Fletcher L
    Nat Biotechnol; 2004 Feb; 22(2):137-8. PubMed ID: 14755277
    [No Abstract]   [Full Text] [Related]  

  • 19. Filters for preparing to meet a venture capitalist.
    Christoffersen R
    Nat Biotechnol; 2003 Jul; 21 Suppl():BE49-50. PubMed ID: 12874981
    [No Abstract]   [Full Text] [Related]  

  • 20. Convincing a venture capitalist to invest in your idea.
    Dooley JF; Dooley JF
    Nat Biotechnol; 2003 Jul; 21 Suppl():BE45-8. PubMed ID: 12874980
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.